Novo Nordisk A/S NVO slashed its 2025 sales forecast Wednesday, citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments in the U.S. market due to competition from compounded versions of the drugs.

諾和諾德公司

<p>諾和諾德公司（Novo Nordisk A/S，股票代碼：NVO）在週三下調了其 2025 年的銷售預測，原因是由於來自藥物複方版本的競爭，其品牌 GLP-1 減肥和糖尿病治療藥物在美國市場的滲透率低於預期</p>

諾和諾德公司的減肥重磅產品因美國複合增長的激增而遭遇挫折，預測被下調